10-Q/A: Centessa Pharmaceuticals Files Amended 10-Q to Correct Typographical Error

Centessa Pharmaceuticals has filed an amended 10-Q report to correct a typographical error in a previously submitted exhibit, with no changes to the financial or other information.

Summary

• Centessa Pharmaceuticals has filed an amendment to its quarterly report on Form 10-Q for the period ended June 30, 2024.
• The amendment, designated as Form 10-Q/A, was filed to correct a typographical error in Exhibit 31.2 of the original filing.
• The original filing was submitted on August 13, 2024.
• The amendment includes certifications from the company's principal executive officer and principal financial officer as required by the Sarbanes-Oxley Act of 2002.
• No other changes were made to the original filing, and the financial and other information remains unchanged.
• The amendment does not reflect any events that may have occurred after the original filing date.
• The company had 113,314,295 ordinary shares outstanding as of August 1, 2024.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, with a minor correction. The sentiment is neutral to slightly positive due to the company's adherence to compliance.

Positives

• The company is taking steps to ensure accuracy in its filings by correcting a typographical error.
• The company has provided certifications from its CEO and CFO, demonstrating compliance with regulatory requirements.

Risks

• The need for an amendment, even for a minor error, could raise questions about the company's internal controls and attention to detail.

Management Comments

• Saurabh Saha, Chief Executive Officer, and John Crowley, Chief Financial Officer, have certified the accuracy of the report.

Industry Context

The filing is a routine regulatory requirement for publicly traded companies, ensuring transparency and compliance with SEC regulations.

Comparison to Industry Standards

• The filing of a 10-Q/A to correct a minor error is not uncommon among publicly traded companies.
• Companies like Amgen, Biogen, and Gilead Sciences also file similar reports to comply with SEC regulations.
• The certifications provided by the CEO and CFO are standard practice and are required by the Sarbanes-Oxley Act.

Stakeholder Impact

• The amendment ensures that stakeholders receive accurate information, maintaining transparency and trust.

Key Dates

Keywords

10-Q, amendment, financial reporting, Centessa Pharmaceuticals, Sarbanes-Oxley, SEC filing, quarterly report